Company profile for G1 Therapeutics, Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our mission is to discover, develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing three clinical-stage therapies for people living with cancer. Trilaciclib is a first-in-class investigational therapy designed to improve out...
Our mission is to discover, develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing three clinical-stage therapies for people living with cancer. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
700 Park Offices Drive Suite 200 Research Triangle Park, NC 27709
Telephone
Telephone
919-213-9835
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/09/18/2948213/0/en/Pharmacosmos-Group-and-G1-Therapeutics-Announce-Successful-Closing-of-Tender-Offer.html

GLOBENEWSWIRE
18 Sep 2024

https://www.globenewswire.com/news-release/2024/09/05/2941161/0/en/Pharmacosmos-Group-and-G1-Therapeutics-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period.html

GLOBENEWSWIRE
05 Sep 2024

https://www.fiercepharma.com/pharma/pharmacosmos-picks-g1-therapeutics-and-its-cosela-merger-worth-405m

FIERCE PHARMA
08 Aug 2024

https://www.globenewswire.com/news-release/2024/08/08/2926725/0/en/G1-Therapeutics-Provides-Second-Quarter-2024-Financial-Results-and-Operational-Highlights.html

GLOBENEWSWIRE
08 Aug 2024

https://www.globenewswire.com/news-release/2024/08/01/2923330/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
01 Aug 2024

https://www.globenewswire.com/news-release/2024/07/25/2918990/0/en/G1-Therapeutics-to-Release-Second-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-August-8-2024.html

GLOBENEWSWIRE
25 Jul 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact G1 Therapeutics, Inc and get a quotation

G1 Therapeutics, Inc is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Trilaciclib Dihydrochloride bulk offered by G1 Therapeutics, Inc

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty